Ex vivo expanded unselected peripheral blood: Progenitor cells reduce posttransplantation neutropenia, thrombocytopenia, and anemia in patients with breast cancer

Blood

Volumn 96, Issue 7, 2000, Pages 2385-2390

  Paquette, Ronald L ^a,b   Dergham, Sanaa T ^a   Karpf, Ellen ^a   Wang, He Jing ^a   Slamon, Dennis J ^a   Souza, Larry ^a   Glaspy, John A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; STEM CELL FACTOR;

ADULT; ANEMIA; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; HUMAN CELL; INFUSION; LEUKOCYTE COUNT; NEUTROPENIA; PRIORITY JOURNAL; STEM CELL; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA;

EID: 0034307373     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.7.2385     Document Type: Article

References (16)

1. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants
2. Comparison of GCSF-primed peripheral blood progenitor cells and bone marrow auto transplantation: Clinical assessment and cost-effectiveness
3. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients
4. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: Hematologic recovery and costs
5. Factors that influence collection and engraftment of autologous peripheral-blood stem cells
6. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy
7. A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients
8. Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: A randomized, controlled trial
9. Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy
10. Ex vivo expansion and differentiation of unselected peripheral blood progenitor cells in serum-free media
11. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients
12. Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo
13. CD34-positive cells isolated from cryopreserved peripheral-blood progenitor cells can be expanded ex vivo and used for transplantation with little or no toxicity
14. + cells in autologous stem cell transplantation for breast cancer
15. Ex-vivo expansion of hematopoietic progenitor cells: Preliminary results in breast cancer
16. Abrogation of post-myeloablative chemotherapy neutropenia by ex-vivo expanded autologous CD34-positive cells